Dimerix Ltd (DXB) - Cash Flow Conversion Efficiency

Latest as of June 2025: 3.087x

Based on the latest financial reports, Dimerix Ltd (DXB) has a cash flow conversion efficiency ratio of 3.087x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$41.30 Million) by net assets (AU$13.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Dimerix Ltd - Cash Flow Conversion Efficiency Trend (1992–2025)

This chart illustrates how Dimerix Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Dimerix Ltd Competitors by Cash Flow Conversion Efficiency

Annual Cash Flow Conversion Efficiency for Dimerix Ltd (1992–2025)

The table below shows the annual cash flow conversion efficiency of Dimerix Ltd from 1992 to 2025.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$13.38 Million AU$39.05 Million 2.919x +857.87%
2024-06-30 AU$18.19 Million AU$-7.00 Million -0.385x +81.96%
2023-06-30 AU$5.96 Million AU$-12.73 Million -2.135x -129.17%
2022-06-30 AU$14.42 Million AU$-13.44 Million -0.932x +78.83%
2021-06-30 AU$1.47 Million AU$-6.46 Million -4.401x -623.25%
2020-06-30 AU$7.76 Million AU$-4.72 Million -0.608x +7.03%
2019-06-30 AU$4.20 Million AU$-2.75 Million -0.655x -39.16%
2018-06-30 AU$6.86 Million AU$-3.23 Million -0.470x +33.66%
2017-06-30 AU$2.63 Million AU$-1.86 Million -0.709x -15.29%
2016-06-30 AU$2.24 Million AU$-1.38 Million -0.615x -205.76%
2015-06-30 AU$2.78 Million AU$-558.55K -0.201x +58.31%
2014-06-30 AU$1.18 Million AU$-568.88K -0.482x +97.30%
2014-04-30 AU$31.22K AU$-558.55K -17.893x -9885.60%
2013-06-30 AU$1.71 Million AU$-305.90K -0.179x +9.01%
2012-06-30 AU$1.18 Million AU$-232.33K -0.197x +5.57%
2011-06-30 AU$1.57 Million AU$-326.54K -0.209x +12.93%
2010-06-30 AU$1.56 Million AU$-373.67K -0.240x +95.32%
2009-06-30 AU$341.98K AU$-1.75 Million -5.113x -114.66%
2008-06-30 AU$1.01 Million AU$-2.40 Million -2.382x -103.42%
2007-06-30 AU$1.41 Million AU$-1.66 Million -1.171x -56.68%
2006-06-30 AU$2.69 Million AU$-2.01 Million -0.747x -405.76%
2005-06-30 AU$10.28 Million AU$-1.52 Million -0.148x -102.79%
2004-06-30 AU$-170.38K AU$-902.37K 5.296x +422.93%
2003-06-30 AU$-565.02K AU$-572.26K 1.013x +147.45%
2002-06-30 AU$282.89K AU$-603.82K -2.135x -1434.07%
2001-06-30 AU$640.43K AU$102.47K 0.160x +74.25%
2000-06-30 AU$5.24 Million AU$481.16K 0.092x -48.60%
1999-06-30 AU$5.77 Million AU$1.03 Million 0.179x +303.76%
1997-06-30 AU$1.96 Million AU$-171.60K -0.088x -29.69%
1996-06-30 AU$1.85 Million AU$-125.03K -0.068x +5.26%
1995-06-30 AU$1.72 Million AU$-123.00K -0.071x -16.09%
1994-06-30 AU$1.74 Million AU$-107.00K -0.061x -147.59%
1993-06-30 AU$1.41 Million AU$-35.00K -0.025x -299.35%
1992-06-30 AU$1.04 Million AU$13.00K 0.012x --

About Dimerix Ltd

AU:DXB Australia Biotechnology
Market Cap
$167.80 Million
AU$237.16 Million AUD
Market Cap Rank
#18624 Global
#493 in Australia
Share Price
AU$0.40
Change (1 day)
-3.66%
52-Week Range
AU$0.30 - AU$0.76
All Time High
AU$0.77
About

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more